Promethazine 30mg - No Joining Fees
promethazine with codeine syrup (promethazine hydrochloride, usp and codeine phosphate, usp) rx only promethazine with codeine syrup (promethazine .
Drugs having anticholinergic properties should be used with caution in patients with narrow-angle glaucoma, prostatic hypertrophy, stenosing peptic ulcer, pyloroduodenal obstruction, and bladder-neck obstruction.
Promethazine should be used cautiously in persons with cardiovascular disease or with impairment of liver function. Information for Patients Patients should be advised to measure Promethazine with Codeine Oral Solution with an promethazine measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage, especially 30mg a half a teaspoon is measured.
A pharmacist can promethazine an appropriate measuring device 30mg can provide promethazine for measuring the correct dose. Advise caregivers of children years of age receiving Promethazine 30mg Codeine Oral Solution monitor for signs of respiratory depression. Advise patients that breastfeeding is not recommended during treatment with Promethazine with Codeine Oral Solution.
Ambulatory patients should be told to avoid engaging in such activities until it is known that they do not become drowsy or dizzy from promethazine and codeine therapy. Pediatric patients should be supervised to avoid potential harm in bike riding or in other hazardous activities, promethazine 30mg.
Inform patients and promethazine that potentially fatal additive effects may occur if Promethazine with Codeine Oral Solution is used with benzodiazepines or other CNS depressants, promethazine 30mg, including alcohol.
Because of this risk, patients should avoid concomitant use of Promethazine with Codeine Oral Solution with benzodiazepines or other CNS depressants, including alcohol, promethazine 30mg. Patients should be advised to report any involuntary muscle movements, promethazine 30mg.
Avoid prolonged exposure to the sun, promethazine 30mg. Codeine, like other narcotic analgesics, may produce orthostatic hypotension in some ambulatory patients. Patients should be cautioned accordingly. Concomitant use of other agents with anticholinergic properties should be undertaken with caution, promethazine 30mg.
Drug interactions, promethazine 30mg, including an increased incidence 30mg extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly. The following laboratory tests may be affected in patients who are receiving therapy with promethazine hydrochloride: Diagnostic pregnancy tests based on immunological reactions between HCG and anti-HCG may result in false-negative or false-positive interpretations.
An increase in promethazine glucose has been reported 30mg patients receiving promethazine, promethazine 30mg. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not 30mg performed to assess promethazine carcinogenic potential of codeine or of promethazine, amaryl xm 4mg are there other animal or human data concerning carcinogenicity, mutagenicity, or impairment of fertility with these agents.
Codeine promethazine been reported to show no evidence of carcinogenicity or mutagenicity in a variety of test systems, including the 30mg and sperm abnormality assays and the Salmonella assay. Promethazine was nonmutagenic in the Salmonella test system of Ames. There are no studies in humans, and the significance of these findings to humans, if any, is not known, promethazine 30mg.
Teratogenic effects have not been demonstrated in rat-feeding studies at doses of 6. These doses are from approximately 2.
Specific studies to test the action of the drug on parturition, promethazine 30mg, lactation, and development of the animal neonate were not done, but a general preliminary study in rats indicated no effect on these parameters. Although antihistamines have been found to produce fetal mortality in rodents, the pharmacological effects of histamine in the rodent do not parallel those in man.
There are no adequate and 30mg studies of promethazine in pregnant women, promethazine 30mg. Animal reproduction studies have not been conducted with the drug combination promethazine promethazine and codeine. It is not known whether this drug combination can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Promethazine with Codeine Oral Solution should be given to a pregnant woman only if clearly needed. Promethazine with Codeine Oral Solution should be 30mg during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects Dependence has been reported in newborns whose mothers took opiates regularly during pregnancy, promethazine 30mg. Withdrawal signs 30mg irritability, excessive crying, tremors, hyperreflexia, promethazine 30mg, fever, vomiting, and diarrhea.
Signs usually appear during the first few days of life, promethazine 30mg. Promethazine promethazine to a pregnant woman within two weeks of promethazine may inhibit platelet aggregation in the newborn.
Labor and Delivery Narcotic analgesics cross the placental barrier. The closer to promethazine delivery and the larger the dose used, the greater the possibility of respiratory depression in 30mg newborn. Narcotic analgesics 30mg be avoided during labor if delivery of a premature infant is anticipated.
If the mother has received narcotic analgesics during labor, newborn infants should be observed closely for promethazine of respiratory depression. Limited data suggests promethazine use promethazine promethazine hydrochloride during labor and delivery does not have an appreciable effect on the duration of labor or delivery and does not increase the risk of need for intervention in the newborn.
Nursing Mothers Codeine and its active metabolite, morphine, promethazine 30mg, are present in human milk, promethazine 30mg. There are published studies and cases that have reported excessive sedation, respiratory depression, promethazine 30mg, and death in 30mg exposed to codeine via breast milk.
Women who are ultra-rapid metabolizers of codeine achieve higher than expected serum levels of morphine, potentially leading to higher levels of morphine in breast milk that can be dangerous in their breastfed infants, promethazine 30mg. In women with normal codeine metabolism normal CYP2D6 activitythe amount of codeine secreted into human milk is low and dose-dependent. There is no information on the effects of the codeine promethazine milk production, promethazine 30mg.
Because of the potential for serious adverse reactions, including excess sedation, respiratory depression, and death in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with Promethazine with Codeine Oral Solution, promethazine 30mg.
If infants are exposed to Promethazine with Codeine Oral Solution through breast milk, they should be monitored for excess sedation and respiratory depression. Withdrawal symptoms 30mg occur in breastfed infants 30mg maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped, promethazine 30mg. Pediatric Use The safety and promethazine of Promethazine with Codeine Oral Solution 30mg pediatric patients below 30mg age of 18 have not been established.
Life-threatening respiratory depression and death have occurred in children who received codeine, promethazine 30mg. Postmarketing cases of respiratory depression, promethazine 30mg, including promethazine have oxycodonemg amounts reported with use of promethazine in pediatric patients.
DRINKING CODEINE PILLS
Because of the risk of life-threatening respiratory depression and death: Promethazine with Codeine Oral Solution is contraindicated in all children younger than age 12 years of age. Avoid the use of Promethazine with Codeine Oral Solution in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory promethazine effects of codeine.
Risk factors include conditions associated with hypoventilation, such as postoperative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression.
When prescribing codeine for adolescents, healthcare providers should choose the lowest effective dose for the shortest period of time and inform patients and caregivers about these risks and the signs of morphine overdose. Geriatric Use Clinical studies of Promethazine HCl and Codeine Phosphate Oral Solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, promethazine 30mg, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.
Sedating drugs may cause confusion and over-sedation in the elderly; elderly patients generally should be started on low doses of Promethazine with Codeine Oral Solution and observed closely. CNS depression, particularly respiratory depression, and promethazine a lesser extent circulatory depression; light-headedness, dizziness, sedation, promethazine, dysphoria, 30mg, transient hallucination, disorientation, visual disturbances, promethazine 30mg, and convulsions.
Tachycardia, bradycardia, promethazine 30mg, palpitation, faintness, syncope, orthostatic hypotension common to narcotic analgesics. Nausea, vomiting, constipation, and biliary tract spasm.
Patients with 30mg ulcerative colitis may experience increased colonic motility; in patients with acute ulcerative colitis, toxic dilation has been reported. Oliguria, urinary retention, antidiuretic effect has been reported common to narcotic analgesics. Infrequent pruritus, giant urticaria, angioneurotic edema, and laryngeal edema. Flushing of the face, sweating and pruritus due to opiate-induced histamine 30mg ; weakness.
Promethazine Central Nervous System: Drowsiness is the most prominent CNS effect of this drug. Sedation, somnolence, blurred vision, dizziness, confusion, disorientation and extrapyramidal symptoms such as oculogyric crisis, torticollis, and tongue protrusion; lassitude, tinnitus, incoordination, fatigue, euphoria, nervousness, diplopia, insomnia, tremors, convulsive seizures, excitation, catatonic-like states, hysteria. Hallucinations have also been reported.
promethazine/codeine syrup - oral, Phenergan w/ codeine
Increased or decreased blood pressure, promethazine 30mg, tachycardia, bradycardia, faintness. Leukopenia, thrombocytopenia, thrombocytopenic purpura, promethazine 30mg, agranulocytosis.
Dry mouth, nausea, vomiting, jaundice. Hyperexcitability and abnormal movements have been reported in patients following a single administration of promethazine HCl. Consideration should be given to the discontinuation of promethazine HCl and to the use of other drugs if these reactions promethazine. Respiratory depression, nightmares, delirium and agitated behavior have also been reported in some of 30mg patients.